Clinical Trial Update: A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety, efficacy, and tolerability of brexpiprazole for agitation in Alzheimer's dementia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Alzheimer Disease

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia | Phase 3 | Status: COMPLETED | Results posted: 2023-09-18